Plus Therapeutics, Inc. (NASDAQ: PSTV) shares began Friday sharply higher, as the Houston-based clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, today announced it reported stockholders' equity of $3 million and therefore satisfied NASDAQ Listing Rule 5550(b)(1), as of June 30, 2025.

The Equity Rule requires listed companies to maintain a minimum of $2.5 million in stockholders' equity.

On June 3, 2025, the NASDAQ Listing Qualifications Department notified the Company that, as of March 31, 2025, the Company no longer satisfied the Equity Rule. Insofar as the Company was subject to a Mandatory Panel Monitor, as that term is defined under Nasdaq Listing Rule 5815(d)(4)(C), through March 6, 2026, with respect to the Equity Rule in particular, the Staff issued a delist determination following such non-compliance.

On June 10, 2025, the Company timely requested a hearing before the Nasdaq Hearings Panel, which stayed any further action by the Staff. The hearing was held on July 15, 2025.

As previously disclosed, on July 22, 2025, the Company was notified by Nasdaq that the Panel had granted the Company's request for an extension to evidence compliance with the Equity Rule subject to the Company's satisfaction of certain conditions.

PSTV shares surged nine cents, or 16%, to 63 cents.

COMTEX_468065525/2559/2025-08-15T09:57:48